{"log_id": 1520902812626376558, "direction": 0, "words_result_num": 40, "words_result": [{"probability": {"variance": 1.5e-05, "average": 0.997453, "min": 0.986379}, "location": {"width": 849, "top": 145, "height": 31, "left": 160}, "words": "告内确定它们之间因果关系的信息尚不充分。在随机对照研究中,观察到转氨酶可升高至"}, {"probability": {"variance": 0.000627, "average": 0.987907, "min": 0.883057}, "location": {"width": 831, "top": 183, "height": 28, "left": 159}, "words": "正常范围值上限(ULN)的3倍以上(非布司他、别嘌醇治疗组的发生率分别为AST:2%,"}, {"probability": {"variance": 0.000773, "average": 0.989652, "min": 0.851605}, "location": {"width": 541, "top": 219, "height": 27, "left": 163}, "words": "2%;ALT:3%,2%)。这些转氨酶升高无剂量-效应关系"}, {"probability": {"variance": 0.000902, "average": 0.991398, "min": 0.814748}, "location": {"width": 788, "top": 257, "height": 29, "left": 201}, "words": "首次使用非布司他之前患者应该进行一次肝功能测试(血清丙氨酸氨基转移酶(ALT)"}, {"probability": {"variance": 0.000228, "average": 0.9938, "min": 0.925734}, "location": {"width": 533, "top": 295, "height": 29, "left": 159}, "words": "AST、碱性磷酸酶和总胆红素),将此结果作为基线水平"}, {"probability": {"variance": 0.000119, "average": 0.996245, "min": 0.935735}, "location": {"width": 808, "top": 331, "height": 30, "left": 199}, "words": "对报告有疲劳、食欲减退、右上腹不适、酱油色尿或黄疸等可能表明肝损害症状的患"}, {"probability": {"variance": 2.2e-05, "average": 0.997579, "min": 0.975011}, "location": {"width": 850, "top": 368, "height": 28, "left": 157}, "words": "者应及时进行肝功能检测。在临床方面,如果患者被发现有肝功能异常(ALT超过参考范"}, {"probability": {"variance": 0.000504, "average": 0.992284, "min": 0.887738}, "location": {"width": 849, "top": 404, "height": 30, "left": 158}, "words": "围上限的3倍以上),应该中止服药,并调查以确定可能的原因。非布司他不应该重新用于"}, {"probability": {"variance": 2.1e-05, "average": 0.997359, "min": 0.982898}, "location": {"width": 452, "top": 442, "height": 26, "left": 158}, "words": "这些肝功能检查异常并没有其他合理解释的患者"}, {"probability": {"variance": 1.6e-05, "average": 0.998104, "min": 0.982044}, "location": {"width": 811, "top": 479, "height": 27, "left": 198}, "words": "若患者的血清ALT超过参考范围的3倍以上,并且其血清总胆红素超过参考范围的2"}, {"probability": {"variance": 3.2e-05, "average": 0.997041, "min": 0.972148}, "location": {"width": 849, "top": 513, "height": 30, "left": 156}, "words": "倍以上,同时排除其他的病因,则该患者此时正处于严重的药物诱发性肝损害的危险之"}, {"probability": {"variance": 2.3e-05, "average": 0.997016, "min": 0.978292}, "location": {"width": 848, "top": 551, "height": 27, "left": 157}, "words": "中,这些患者不应该再重新使用非布司他。对于那些血清ALT或胆红素升高幅度较小且有"}, {"probability": {"variance": 6e-06, "average": 0.998018, "min": 0.990684}, "location": {"width": 496, "top": 587, "height": 28, "left": 156}, "words": "其他合理解释的患者来说,采用非布司他治疗需慎重"}, {"probability": {"variance": 8.4e-05, "average": 0.995377, "min": 0.971307}, "location": {"width": 177, "top": 624, "height": 26, "left": 198}, "words": "继发性高尿酸血症"}, {"probability": {"variance": 0.000274, "average": 0.995101, "min": 0.89686}, "location": {"width": 809, "top": 660, "height": 29, "left": 198}, "words": "尚无本品应用于继发性高尿酸血症患者(包括器官移植受体)的研究,因此不建议将本"}, {"probability": {"variance": 0.000299, "average": 0.99232, "min": 0.901735}, "location": {"width": 851, "top": 696, "height": 33, "left": 156}, "words": "品应用于尿酸盐大量升高的患者(如恶性疾病、 Lesch- Nyhan综合征)。少数病例显示,尿"}, {"probability": {"variance": 1.9e-05, "average": 0.996962, "min": 0.981139}, "location": {"width": 389, "top": 735, "height": 27, "left": 157}, "words": "中黄嘌呤浓度明显升高后可在泌尿道沉积"}, {"probability": {"variance": 1.6e-05, "average": 0.99584, "min": 0.988394}, "location": {"width": 250, "top": 771, "height": 29, "left": 161}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0, "average": 0.999913, "min": 0.999854}, "location": {"width": 45, "top": 809, "height": 24, "left": 198}, "words": "孕妇"}, {"probability": {"variance": 0.000235, "average": 0.994139, "min": 0.914931}, "location": {"width": 810, "top": 843, "height": 33, "left": 196}, "words": "FDA妊娠安全分类为C类:在孕妇中未进行充分的对照研究。所以唯有确认潜在益处"}, {"probability": {"variance": 2e-05, "average": 0.996786, "min": 0.978501}, "location": {"width": 453, "top": 881, "height": 27, "left": 155}, "words": "大于对胎儿风险时,妊娠期间才能使用非布司他"}, {"probability": {"variance": 0.000444, "average": 0.993459, "min": 0.860707}, "location": {"width": 807, "top": 917, "height": 32, "left": 198}, "words": "口服给予大鼠和家兔48mg/kg(按体表面积换算,分别相当于人用剂量80mg/d时血浆"}, {"probability": {"variance": 0.000244, "average": 0.993154, "min": 0.916286}, "location": {"width": 851, "top": 955, "height": 28, "left": 154}, "words": "暴露量的40和51倍)非布司他时,在器官形成期未显示致畸性。然而,在器官形成期和哺"}, {"probability": {"variance": 0.000142, "average": 0.993104, "min": 0.953136}, "location": {"width": 848, "top": 990, "height": 34, "left": 155}, "words": "乳期,大鼠口服剂量达到48mgkg(按体表面积换算,相当于人用剂量80mg/d时血浆暴露"}, {"probability": {"variance": 1e-05, "average": 0.997853, "min": 0.983372}, "location": {"width": 655, "top": 1030, "height": 28, "left": 155}, "words": "量的40倍)时,可导致新生大鼠死亡率增高和减少新生大鼠体重增加"}, {"probability": {"variance": 0.100992, "average": 0.646951, "min": 0.229582}, "location": {"width": 67, "top": 1041, "height": 30, "left": 885}, "words": " mm3 /"}, {"probability": {"variance": 0, "average": 0.999199, "min": 0.998145}, "location": {"width": 109, "top": 1068, "height": 25, "left": 197}, "words": "哺乳期妇女"}, {"probability": {"variance": 0.00403, "average": 0.986623, "min": 0.606933}, "location": {"width": 808, "top": 1102, "height": 32, "left": 195}, "words": "对大鼠的研究发现非布司他可经乳汁排泄。但尚不知非布司他是否会经人乳排泄。由"}, {"probability": {"variance": 7e-06, "average": 0.998347, "min": 0.988065}, "location": {"width": 514, "top": 1141, "height": 27, "left": 156}, "words": "于很多药物可分泌到乳汁,因此哺乳期妇女应慎用本品"}, {"probability": {"variance": 3e-06, "average": 0.998277, "min": 0.995455}, "location": {"width": 120, "top": 1178, "height": 26, "left": 161}, "words": "【儿童用药】"}, {"probability": {"variance": 1.8e-05, "average": 0.997532, "min": 0.982953}, "location": {"width": 484, "top": 1214, "height": 26, "left": 197}, "words": "尚未确定本品治疗18岁以下患者的安全性和有效性"}, {"probability": {"variance": 6e-06, "average": 0.996625, "min": 0.99372}, "location": {"width": 118, "top": 1251, "height": 26, "left": 160}, "words": "【老年用药】"}, {"probability": {"variance": 3.1e-05, "average": 0.99712, "min": 0.976816}, "location": {"width": 809, "top": 1288, "height": 30, "left": 196}, "words": "老年患者无需调整剂量。据国外文献报道,在非布司他临床研究中,65岁及以上者占"}, {"probability": {"variance": 0.001263, "average": 0.988981, "min": 0.825505}, "location": {"width": 849, "top": 1327, "height": 31, "left": 155}, "words": "受试者总数的16%,75岁及以上者占4%。比较不同年龄组的受试者,在有效性和安全性方"}, {"probability": {"variance": 8e-05, "average": 0.996261, "min": 0.947759}, "location": {"width": 837, "top": 1367, "height": 27, "left": 155}, "words": "面无临床显著性差异,但不排除有些老年患者对本品较敏感。老年受试者(65岁及以上)"}, {"probability": {"variance": 0.009253, "average": 0.963408, "min": 0.505205}, "location": {"width": 642, "top": 1403, "height": 27, "left": 156}, "words": "多次口服非布司他后,Cmx、AUC24与年轻受试者(18~40岁)相似"}, {"probability": {"variance": 1.1e-05, "average": 0.99726, "min": 0.98938}, "location": {"width": 161, "top": 1440, "height": 27, "left": 160}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.012969, "average": 0.961344, "min": 0.570076}, "location": {"width": 275, "top": 1479, "height": 26, "left": 195}, "words": "1.黄嘌呤氧化酶底物类药物"}, {"probability": {"variance": 0.005843, "average": 0.981722, "min": 0.522261}, "location": {"width": 807, "top": 1516, "height": 30, "left": 196}, "words": "非布司他是一种黄嘌呤氧化酶(X0)抑制剂。根据一项在健康受试者上开展的药物相"}, {"probability": {"variance": 0.000912, "average": 0.988831, "min": 0.813484}, "location": {"width": 846, "top": 1553, "height": 30, "left": 155}, "words": "互作用研究,非布司他改变茶碱(XO的一种底物)在人体内的代谢。因此,非布司他与茶"}], "language": 3}